CEL-SCI Home Page
preload preload

Press Releases

Corporate Presentations

Press Releases

May 22, 2015
NEW STORY CEL-SCI Prices Up To $16 Million Public Offering of Common Stock and Warrants

May 21, 2015
NEW STORY CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants

May 13, 2015
NEW STORY CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Italy

May 11, 2015
NEW STORY CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Spain

May 8, 2015
NEW STORY CEL-SCI Corporation Reports Second Quarter Fiscal Year 2015 Financial Results

May 6, 2015
NEW STORY CEL-SCI Announces Proposed Public Offering of Common Stock

May 1, 2015
NEW STORY CEL-SCI Reports 4th Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial

April 13, 2015
NEW STORY UK's Aintree University Hospital Joins CEL-SCI's Phase III Head and Neck Cancer Trial

April 1, 2015
NEW STORY CEL-SCI Reports 3rd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial

March 3, 2015
NEW STORY CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial

February 27, 2015
NEW STORY CEL-SCI Completes Key Milestone with Clearance to Conduct Phase III Trial in 21 Countries

February 20, 2015
NEW STORY CEL-SCI to Participate in Ascendiant's Quarterly Management Discussion Series Today, Friday February 20 at 11 AM Eastern Time

February 19, 2015
NEW STORY CEL-SCI's Phase III Head and Neck Cancer Trial Cleared to Begin Patient Enrollment in Malaysia, the 20th Country to Join the Trial

February 18, 2015
NEW STORY CEL-SCI to Present At 3rd Annual Sachs Cancer Bio Partnering and Investment Forum

February 11, 2015
NEW STORY The Philippines is the 19th Country to Clear CEL-SCI for Patient Enrollment in Its Phase III Head and Neck Cancer Trial

February 6, 2015
NEW STORY CEL-SCI Corporation Reports First Quarter 2015 Financial Results

February 5, 2015
NEW STORY CEL-SCI to Present At 17th Annual BIO CEO & Investor Conference

February 2, 2015
NEW STORY CEL-SCI Reports Record Monthly Patient Enrollment in Its Phase III Head and Neck Cancer Trial

January 26, 2015
NEW STORY CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romania

January 9, 2015
NEW STORY CEL-SCI to Present at Biotech Showcase 2015

January 6, 2015
NEW STORY Date Set For Arbitration Trial between CEL-SCI And Clinical Research Organization Inventiv

January 5, 2015
NEW STORY CEL-SCI's 2014 Patient Enrollment Increases Eight-Fold Over 2013 in Its Phase III Head and Neck Cancer Trial

December 23, 2014
CEL-SCI Reports Fiscal 2014 Financial Results and Clinical & Corporate Developments

December 8, 2014
CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial with Addition of 7 More Clinical Sites

October 24, 2014
CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million

October 21, 2014
NEW STORY CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering

September 29, 2014
CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients

July 15, 2014
CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment

July 11, 2014
CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development: All Things Considered Conference

 

ADDITIONAL RELEASES
View All Corporate Press Releases


Phase III Clinical Trial Monthly Enrollment Chart

Number of Patients Enrolled per month since the transfer to the new CROs.

Phase III Enrollment Chart


 

THE CEL-SCI STORY